{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:46:24Z","timestamp":1785743184744,"version":"3.56.0"},"reference-count":11,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>Beyond established rare fusions, such as ALK and ROS1, emerging ultrarare fusions involving receptor tyrosine kinases or their ligands, including EGFR\u2013SHC1, further guide us to uncover novel mechanisms of oncogenic activation and corresponding treatment strategies. Collectively, rare and ultrarare genomic events are driving precision oncology toward an increasingly individualized era of \u201cultraprecision\u201d cancer therapy.<\/jats:p>\n                  <jats:p>See related article by Zheng et al., p. 1573<\/jats:p>","DOI":"10.1158\/2159-8290.cd-26-1062","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:14:18Z","timestamp":1785741258000},"page":"1480-1482","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare Fusions, Real Targets: Ultraprecision Oncology in Lung Cancer"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-1185","authenticated-orcid":false,"given":"Xiuning","family":"Le","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Thoracic Head and Neck Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-8812","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[{"name":"2Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026080303141034500_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026080303141034500_bib2","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026080303141034500_bib3","article-title":"Long-term efficacy and safety of taletrectinib in patients with ROS1+ non-small cell lung cancer: results from the phase II TRUST-I study","author":"Li","year":"2026  21","journal-title":"J Clin Oncol"},{"key":"2026080303141034500_bib4","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080303141034500_bib5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse","year":"2026","journal-title":"Nat Med"},{"key":"2026080303141034500_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jtho.2023.06.020","article-title":"MET fusions in NSCLC: clinicopathologic features and response to MET inhibition","volume":"19","author":"Riedel","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026080303141034500_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-021-04135-5","article-title":"The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer","volume":"600","author":"Izumi","year":"2021","journal-title":"Nature"},{"key":"2026080303141034500_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/2159-8290.CD-16-0075","article-title":"EGFR fusions as novel therapeutic targets in lung cancer","volume":"6","author":"Konduri","year":"2016","journal-title":"Cancer Discov"},{"key":"2026080303141034500_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/2159-8290.CD-17-1004","article-title":"Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"2026080303141034500_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41571-023-00733-6","article-title":"Rare molecular subtypes of lung cancer","volume":"20","author":"Harada","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026080303141034500_bib11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/2159-8290.CD-25-1936","article-title":"The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer","volume":"16","author":"Zheng","year":"2026","journal-title":"Cancer Discov"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/8\/1480\/3818188\/cd-26-1062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/8\/1480\/3818188\/cd-26-1062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:14:20Z","timestamp":1785741260000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/1480\/787110\/Rare-Fusions-Real-Targets-Ultraprecision-Oncology"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":11,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-26-1062","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}